EMA guideline: Synthetic peptides from June 2026

International: The European Medicines Agency (EMA) has comprehensively revised its guideline on the development and manufacture of synthetic peptides (EMA/CHMP/CVMP/QWP/367182/2025). The new version takes effect on 1 June 2026, replaces the 2022 version, and tightens the quality requirements for peptide active substances. For users, this means stricter rules may increase quality, but they do not change the grey market risk.

Summary of the new quality requirements for synthetic peptides

• The EMA guideline EMA/CHMP/CVMP/QWP/367182/2025 on synthetic peptides becomes binding for all marketing authorisation holders in the EU and the EEA as of 1 June 2026.
• The revision tightens requirements for the manufacturing process, characterisation, and specifications of synthetic peptides.
• New provisions cover, for the first time, conjugation, product development, and the use of biological peptides as reference medicinal products.
• For users, the theoretical quality requirements increase, while the risk of purchases on the grey market remains unchanged and high.

What does the new EMA guideline for synthetic peptides regulate?

The new EMA guideline defines the standards for the development and manufacture of synthetic peptides in the pharmaceutical industry. It complements existing guidelines on the chemistry of active substances and closes specific gaps for peptide active ingredients. According to the EMA (2025), it covers the manufacturing process, characterisation, specifications, and analytical control, as well as requirements for conjugation and product development.^[1]

Pharmaceutical manufacturers must in future provide more detailed evidence that their products meet strict purity and quality standards. This includes in-depth testing for impurities and precise molecular characterisation. For users, this standard serves as a reference point for distinguishing quality in the legal pharmaceutical segment from uncontrolled grey market products.

Why is the revision important for peptide users and clinical studies?

The revision signals stricter regulation of synthetic peptides within the EU, which has implications for pharmaceutical manufacturers, compounding pharmacies, and clinical studies. Users who source peptides benefit from higher safety requirements in the legal sector. In contrast, the situation on the grey market remains risky, as there is no obligation there to comply with these EMA standards.

Using GLP-1 - a peptide hormone for blood sugar regulation - as an example, the quality gap becomes clear: while legal preparations must clear the new hurdles, grey market products offer no guarantee of identical manufacturing quality. To minimise risks, users should prefer providers that align with pharmaceutical standards and regularly check our warning list for peptide providers.

When does the new regulation take effect, and what follows in the USA?

The new guideline officially takes effect on 1 June 2026, with the EMA finally confirming this date in April 2026.^[5] Manufacturers are using the current transition period to adapt their processes. For users, this is a suitable time to critically question their sources: reputable providers often substantiate the quality of their active substances with a certificate of analysis (CoA) or HPLC tests. In our peptide library, you will find further information for classifying different active substances.

Internationally, a similar trend towards tightening is emerging: in the USA, the FDA is considering in 2026 whether to add peptides to the restrictive compounding list. These global developments indicate that requirements for peptide safety are rising worldwide. Users should stay informed and not rely on unverified advertising promises when choosing their sources.

Important note on information

This article is for information purposes only and does not constitute medical advice. It does not provide recommendations on dosing or specific sources for obtaining peptides. Always consult qualified medical personnel for health-related questions.